Copyright
©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2007; 13(46): 6191-6196
Published online Dec 14, 2007. doi: 10.3748/wjg.v13.i46.6191
Published online Dec 14, 2007. doi: 10.3748/wjg.v13.i46.6191
Table 3 CDAI and drug therapy in mtNOD2 and wtNOD2 patients
| mtNOD2 (n = 20) | wtNOD2 (n = 27) | |
| CDAI | 24.5 | 25.2 |
| Active disease | 14 | 16 |
| Steroids | 7 | 9 |
| Methotrexate | 1 | 1 |
| Azathioprine | 4 | 5 |
| Aminosalicylic acid | 6 | 8 |
| Salazopyrine | 4 | 4 |
| Infliximab | 1 | 1 |
| Thalidomide | 4 | 5 |
- Citation: Granzotto M, Fabbro E, Maschio M, Martelossi S, Quaglia S, Tommasini A, Presani G, Ventura A. Heterozygous nucleotide-binding oligomerization domain-2 mutations affect monocyte maturation in Crohn’s disease. World J Gastroenterol 2007; 13(46): 6191-6196
- URL: https://www.wjgnet.com/1007-9327/full/v13/i46/6191.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i46.6191